Abbott Laboratories (ABT, Financial) anticipates achieving an adjusted operating margin of approximately 23.5% of its sales by the fiscal year 2025. This projection reflects the company's focus on enhancing its financial performance and operational efficiency in the coming years. Investors and analysts are closely monitoring these developments as they could have significant implications for Abbott's future growth and profitability.
Wall Street Analysts Forecast
Based on the one-year price targets offered by 24 analysts, the average target price for Abbott Laboratories (ABT, Financial) is $143.47 with a high estimate of $159.00 and a low estimate of $120.12. The average target implies an upside of 8.90% from the current price of $131.74. More detailed estimate data can be found on the Abbott Laboratories (ABT) Forecast page.
Based on the consensus recommendation from 29 brokerage firms, Abbott Laboratories's (ABT, Financial) average brokerage recommendation is currently 2.1, indicating "Outperform" status. The rating scale ranges from 1 to 5, where 1 signifies Strong Buy, and 5 denotes Sell.
Based on GuruFocus estimates, the estimated GF Value for Abbott Laboratories (ABT, Financial) in one year is $121.36, suggesting a downside of 7.88% from the current price of $131.74. GF Value is GuruFocus' estimate of the fair value that the stock should be traded at. It is calculated based on the historical multiples the stock has traded at previously, as well as past business growth and the future estimates of the business' performance. More detailed data can be found on the Abbott Laboratories (ABT) Summary page.
